Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Cardiovascular diseases

Antidepressants linked with increased risk of VTE

Deep vein thrombosis, stockings

Source: Shutterstockcom

In a study of nearly 1 million patients, researchers observed a 31% increased chance of venous thromboembolism in patients with depression compared to those without depression

Depression and use of antidepressants are each associated with an increased risk of venous thromboembolism (VTE), a study has revealed[1]. Although the mechanism underlying these associations is not yet understood.

In the first systematic review and meta-analysis of eight published observational studies, using data from 960,113 participants, researchers evaluated the associations of depression and antidepressant use with VTE risk.

Individuals taking antidepressants were 27% more likely to have VTE than those not taking antidepressants. Tricyclic antidepressants, selective serotonin reuptake inhibitors and other antidepressants were associated with a 16%, 12% and 59% increase risk of VTE, respectively.

In the studies comparing patients with depression compared to those without depression, the risk of VTE was increased by 31%.

VTE is an important cause of morbidity, mortality and associated with high health costs, the researchers said, and despite advances in the knowledge of risk factors for VTE and its treatment, it remains a global public health problem.

But they said the findings added to accumulating evidence that a relationship exists between depression, antidepressant use and VTE.

“These findings are very useful to me as both a clinician and a researcher,” said Setor Kunutsor, a research fellow from the Musculoskeletal Research Unit at Bristol Medical School and the lead researcher on the study. “It gives me the information I need, especially when prescribing antidepressant medications to my patients.”

Further studies are still warranted to establish the role of depression and antidepressant use in VTE development, their potential causative pathways, and if there is a class effect of antidepressants on VTE, the researchers concluded.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20205247

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Deep vein thrombosis, stockings

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.